PharmaLeaders - Clinical News

Inspire Announces Amendment to Ophthalmic Collaboration

Administrator — Wed, 25 Aug 2010 10:30:00 +0000

DURHAM, N.C.--(BUSINESS WIRE)-- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS^® (cyclosporine ophthalmic emulsion) 0.05% and any...

Maven Semantic: Biomaterials Research Database

Administrator — Wed, 25 Aug 2010 10:22:00 +0000

Search Over 22,000 People and Over 2,000 Biomaterials Research Organisations

DUBLIN--(BUSINESS WIRE)-- Maven Semantic (http://www.mavensemantic.com ) announces updates to their Biomaterials research database.

The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life...

KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company's ...

Administrator — Wed, 25 Aug 2010 10:00:00 +0000

NORTH LIBERTY, Iowa, Aug. 25 /PRNewswire/ -- KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same", U.S. Patent No. 7,776,917 B2. This patent, combined with KemPharm's recently issued U.S. Patent No. 7,772,222, provides broad protection of the Company's Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder. The patent covers the Company's lead clinical candidate KP106, a new...

ZymoGenetics Announces Completion of Enrollment in Phase 2b Clinical Trial with PEG-Interferon ...

Administrator — Wed, 25 Aug 2010 10:00:00 +0000

SEATTLE--(BUSINESS WIRE)-- ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection. ZymoGenetics is investigating PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for the treatment of HCV infection.

“We’re very...

Maven Semantic: Database of German Life Sciences Research Professionals

Administrator — Wed, 25 Aug 2010 09:58:00 +0000

Search Over 258,000 People and Over 10,000 Research Organisations

DUBLIN--(BUSINESS WIRE)-- Maven Semantic (http://www.mavensemantic.com ) announces updates to their German healthcare research database.

The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector....